The United States Patent and Trademark Office(USPTO)has extended the Spectrum Pharmaceuticals US patent covering Folotyn(pralatrexate injection)for five years. The extension,which was granted through the Hatch-Waxman Act,postpones the ...
Tags: USPTO, Spectrum Folotyn Patent, pralatrexate injection